European Companies Search Engine
EU funding (€12M): Amyloid imaging to Prevent Alzheimer’s Disease – Sofia ref.: 115952 Hor 1 Oct 2016 EU Research and Innovation programme "Horizon"
Overview
Text
Amyloid imaging to Prevent Alzheimer’s Disease – Sofia ref.: 115952
Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD). Depiction of brain β-amyloid in vivo can support an early diagnosis, and even provide an opportunity for consider secondary prevention of AD. Currently, however, the value of β-amyloid PET remains elusive, reason why this procedure is typically not reimbursed. Understanding the value of imaging of β-amyloid using positron emission tomography (PET) provides a unique opportunity to achieve 3 major goals: 1) improve the diagnostic workup of patients suspected of AD and their management; 2) stratify risk for AD and select homogenous groups for intervention; and 3) quantify treatment effects more accurately. AMYPAD will address the above objectives by studying the onset, dynamics, and clinical relevance of brain β-amyloid in the spectrum from normal aging to preclinical and prodromal AD. We will use β-amyloid-PET in an unprecedented large number of subjects (n=4000) from population studies, as well as memory clinics cohorts, with repeat imaging in up to 2000. In close collaboration with EPAD (www.ep-ad.org), the cohorts will be followed with to determine (surrogate) outcomes of cognitive decline and neurodegeneration. Lead from VU-VUmc, the Consortium brings together a word-class team of highly synergistic partners from across Europe constituting a highly experienced and efficient β-amyloid imaging network including the most active European PET sites, to ensure effective tracer delivery, access to patients and expertise to technical knowledge and disease modelling. AMYPAD will establish the true value of β-amyloid PET across the severity range of AD. Patients and clinicians will benefit from better and cost-effective diagnostic procedures and management, while academics and industry will benefit from better disease understanding, clear reimbursement strategy and more rationale and efficient clinical trial design.
Funded Companies:
| Company name | Funding amount |
| Alzheimer Europe | €222,750 |
| Centre Hospitalier Universitaire de Toulouse | €1,061,578 |
| Fundacio Barcelonabeta Brain Research Center | €2,058,495 |
| GE Healthcare Ltd. | €0.00 |
| Ixico Technologies Ltd. | €1,196,136 |
| Janssen Pharmaceutica N.V. | €0.00 |
| Karolinska Institutet | €753,375 |
| Klinikum DER Universitaet ZU Koeln | €605,357 |
| Life Molecular Imaging Ltd. | €0.00 |
| Region Stockholm | €0.00 |
| Stichting Amsterdam UMC | €3,875,739 |
| Stichting Radboud Universitair Medisch Centrum | €175,000 |
| Stichting Radboud Universiteit | €0.00 |
| Synapse Research Management Partners SL | €491,090 |
| The University of Edinburgh | €568,590 |
| Universite DE Geneve | €0.00 |
| University College London | €991,776 |
Source: https://cordis.europa.eu/project/id/115952
The filing refers to a past date, and does not necessarily reflect the current state.
